254 related articles for article (PubMed ID: 28552625)
21. Novel Treatment Concepts in Psoriatic Arthritis.
Boyd T; Kavanaugh A
Rheum Dis Clin North Am; 2015 Nov; 41(4):739-54. PubMed ID: 26476230
[TBL] [Abstract][Full Text] [Related]
22. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
23. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
[TBL] [Abstract][Full Text] [Related]
24. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
Salvarani C; Cantini F; Olivieri I
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
[TBL] [Abstract][Full Text] [Related]
25. Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?
Lubrano E; Soriano E; FitzGerald O
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S54-8. PubMed ID: 24129139
[TBL] [Abstract][Full Text] [Related]
26. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.
Torre Alonso JC; Díaz Del Campo Fontecha P; Almodóvar R; Cañete JD; Montilla Morales C; Moreno M; Plasencia-Rodríguez C; Ramírez García J; Queiro R
Reumatol Clin (Engl Ed); 2018; 14(5):254-268. PubMed ID: 29111261
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of psoriatic arthritis.
Balakrishnan C; Madnani N
Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
[TBL] [Abstract][Full Text] [Related]
28. Psoriatic arthritis: current therapy and future approaches.
Huynh D; Kavanaugh A
Rheumatology (Oxford); 2015 Jan; 54(1):20-8. PubMed ID: 25125588
[TBL] [Abstract][Full Text] [Related]
29. Use of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologists.
Aimo C; Cosentino VL; Sequeira G; Kerzberg E
Rheumatol Int; 2019 Apr; 39(4):723-727. PubMed ID: 30830285
[TBL] [Abstract][Full Text] [Related]
30. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
Simone D; Nowik M; Gremese E; Ferraccioli GF
J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
[TBL] [Abstract][Full Text] [Related]
31. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs.
Lubrano E; Scarpa R
Reumatismo; 2012 Jun; 64(2):107-12. PubMed ID: 22690387
[TBL] [Abstract][Full Text] [Related]
32. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.
Soriano ER
J Rheumatol Suppl; 2012 Jul; 89():67-70. PubMed ID: 22751597
[TBL] [Abstract][Full Text] [Related]
33. The Changing Face of Clinical Trials in Psoriatic Arthritis.
Ogdie A; Coates L
Curr Rheumatol Rep; 2017 Apr; 19(4):21. PubMed ID: 28365920
[TBL] [Abstract][Full Text] [Related]
34. Etanercept in the treatment of psoriatic arthritis.
Puig L; López-Ferrer A; Laiz A
Actas Dermosifiliogr; 2015 May; 106(4):252-9. PubMed ID: 25455504
[TBL] [Abstract][Full Text] [Related]
35. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
[TBL] [Abstract][Full Text] [Related]
36. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
37. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
[TBL] [Abstract][Full Text] [Related]
38. Psoriatic arthritis: update on pathophysiology, assessment and management.
Mease PJ
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i77-84. PubMed ID: 21339225
[TBL] [Abstract][Full Text] [Related]
39. A review of disease activity measures for psoriatic arthritis: what is the best approach?
Her M; Kavanaugh A
Expert Rev Clin Immunol; 2014 Sep; 10(9):1241-54. PubMed ID: 25088300
[TBL] [Abstract][Full Text] [Related]
40. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Coates LC; Kavanaugh A; Mease PJ; Soriano ER; Laura Acosta-Felquer M; Armstrong AW; Bautista-Molano W; Boehncke WH; Campbell W; Cauli A; Espinoza LR; FitzGerald O; Gladman DD; Gottlieb A; Helliwell PS; Husni ME; Love TJ; Lubrano E; McHugh N; Nash P; Ogdie A; Orbai AM; Parkinson A; O'Sullivan D; Rosen CF; Schwartzman S; Siegel EL; Toloza S; Tuong W; Ritchlin CT
Arthritis Rheumatol; 2016 May; 68(5):1060-71. PubMed ID: 26749174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
